| Not Yet Recruiting | Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients NCT06397781 | Boston Children's Hospital | Phase 4 |
| Withdrawn | Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis NCT03553615 | Stanford University | Phase 2 |
| Not Yet Recruiting | A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisab NCT07519174 | Foundation University Islamabad | N/A |
| Not Yet Recruiting | Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis NCT07162896 | Shalamar Institute of Health Sciences | Phase 3 |
| Not Yet Recruiting | Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis NCT07377838 | EHL Bio Co., Ltd. | Phase 3 |
| Not Yet Recruiting | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Derm NCT07527923 | Regeneron Pharmaceuticals | Phase 1 |
| Not Yet Recruiting | Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica NCT07448363 | Caja Costarricense de Seguro Social | — |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis NCT07479615 | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 |
| Not Yet Recruiting | A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. NCT07533851 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 |
| Recruiting | Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease an NCT07262983 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies NCT07228962 | King's College London | — |
| Recruiting | A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants NCT07488065 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Clinical Study to Evaluate SM17 for Atopic Dermatitis NCT07445919 | SinoMab BioScience Ltd | Phase 2 |
| Not Yet Recruiting | Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ NCT07358000 | University Hospital, Caen | N/A |
| Not Yet Recruiting | The Impact of Dietary Salt on the Severity of Eczema NCT07447063 | University of California, San Francisco | Phase 4 |
| Not Yet Recruiting | Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in T NCT07434076 | Shanghai Yueyang Integrated Medicine Hospital | — |
| Not Yet Recruiting | Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment NCT07437534 | Hayat Abad Medical Complex, Peshawar | Phase 4 |
| Not Yet Recruiting | Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete NCT07444008 | NovoNatum Ltd | N/A |
| Recruiting | The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopi NCT07467564 | Sanofi | — |
| Recruiting | A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixe NCT07358156 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Recruiting | A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis NCT07399067 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis NCT07193589 | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 |
| Recruiting | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD NCT07441395 | Corvus Pharmaceuticals, Inc. | Phase 2 |
| Enrolling By Invitation | Thera-Clean® Microbubbles System in Patients With Skin Diseases NCT07050810 | Northwestern University | EARLY_Phase 1 |
| Recruiting | Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had I NCT06899204 | Pfizer | — |
| Recruiting | Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome NCT07242638 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Recruiting | A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With NCT07223697 | Hoffmann-La Roche | Phase 2 |
| Not Yet Recruiting | URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis NCT07295678 | CEN Biotech | N/A |
| Not Yet Recruiting | Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis NCT07333378 | Pontificia Universidad Catolica de Chile | N/A |
| Not Yet Recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis NCT07352566 | University of California, San Francisco | Phase 4 |
| Not Yet Recruiting | Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective NCT07323394 | PeriPharm | — |
| Not Yet Recruiting | LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in NCT07336641 | Fondazione ISIDE | — |
| Recruiting | A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis NCT07330934 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in NCT07277660 | UCB Biopharma SRL | Phase 2 |
| Recruiting | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months NCT07265479 | Organon and Co | Phase 3 |
| Recruiting | PALLAS Laser for Skin Diseases NCT07250997 | Szeged University | N/A |
| Recruiting | A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Sever NCT06807281 | Pfizer | Phase 3 |
| Not Yet Recruiting | A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Dev NCT07264335 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis NCT07217015 | Kymera Therapeutics, Inc. | Phase 2 |
| Recruiting | Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in NCT07297602 | Nora Mohamed Abdelrazik | Phase 2 |
| Active Not Recruiting | A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema NCT07216027 | Pfizer | Phase 2 |
| Recruiting | This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Wh NCT07290803 | Sanofi | — |
| Recruiting | A Clinical Trial Evaluating a Probiotic Emollient for the Treatment of Pediatric Atopic Dermatitis NCT07072273 | Biogaia New Sciences AB | N/A |
| Recruiting | Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to NCT07220577 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Methotrexat to Hand Eczema in the BIOSKIN Cohort NCT07338305 | Lone Skov | — |
| Completed | A Clinical Study to Evaluate SM17 in Healthy Participants NCT07466940 | SinoMab BioScience Ltd | Phase 1 |
| Active Not Recruiting | A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medic NCT07190430 | Pfizer | Phase 1 |
| Not Yet Recruiting | Clinical Trial to Evaluate the Effect of a Probiotic Mixture in the Treatment of Atopic Dermatitis in Children NCT05443490 | Bionou Research, S.L. | N/A |
| Not Yet Recruiting | Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Wee NCT07014007 | Pierre Fabre Dermo Cosmetique | N/A |
| Completed | A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstrea NCT07172321 | Pfizer | Phase 1 |
| Not Yet Recruiting | A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis NCT07106372 | Keymed Biosciences Co.Ltd | Phase 3 |
| Recruiting | Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction NCT07183423 | Makati Medical Center | N/A |
| Not Yet Recruiting | Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis NCT07054736 | Zhejiang Kanova Biopharmaceutical Co., LTD | Phase 2 |
| Recruiting | A Study Evaluating TRIV-509 in Atopic Dermatitis NCT07167758 | Triveni Bio | Phase 2 |
| Recruiting | A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis NCT07239947 | Bambusa Therapeutics | Phase 1 |
| Recruiting | Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescent NCT06988605 | Galderma R&D | — |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis NCT07015762 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Recruiting | A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis) NCT07355075 | Turn Therapeutics | Phase 2 |
| Recruiting | Lebrikizumab in Moderate-to-severe Atopic Dermatitis NCT06906497 | Johann E Gudjonsson MD PhD | Phase 4 |
| Not Yet Recruiting | A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China NCT07042113 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and NCT06934980 | Incyte Corporation | — |
| Recruiting | Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis NCT06947980 | Keymed Biosciences Co.Ltd | Phase 2 |
| Recruiting | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old NCT06832618 | Incyte Corporation | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic De NCT07037901 | Inmagene LLC | Phase 2 |
| Recruiting | Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Ne NCT06983561 | Pierre Fabre Dermo Cosmetique | — |
| Recruiting | A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) NCT07006792 | Eli Lilly and Company | Phase 4 |
| Active Not Recruiting | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic D NCT07027527 | Apogee Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis NCT07011706 | Aclaris Therapeutics, Inc. | Phase 2 |
| Completed | The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers NCT06974292 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 |
| Recruiting | Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis NCT06880276 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to NCT06947993 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis NCT07003425 | Apogee Therapeutics, Inc. | Phase 2 |
| Recruiting | Sodium in the Skin and Atopic Dermatitis NCT06998446 | University of California, San Francisco | — |
| Not Yet Recruiting | Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatiti NCT06487000 | Enzychem Lifesciences Corporation | Phase 2 |
| Not Yet Recruiting | Study of Stapokibatrt in Children Subjects With Atopic Dermatitis NCT06956196 | Keymed Biosciences Co.Ltd | Phase 3 |
| Active Not Recruiting | Efficacy of Topical Cannabidiol for Eczema NCT06994520 | Khon Kaen University | Phase 2 |
| Completed | Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate A NCT06891040 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 |
| Completed | Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis ( NCT06945458 | Kymera Therapeutics, Inc. | Phase 1 |
| Recruiting | Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) NCT06504160 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis NCT06922565 | Shanghai Yueyang Integrated Medicine Hospital | N/A |
| Not Yet Recruiting | A Phase Ⅲ Comparative Study of QL2108 to Dupixent® NCT06884891 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe At NCT06863961 | Hoffmann-La Roche | Phase 2 |
| Recruiting | A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Mod NCT06946641 | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 |
| Recruiting | Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. NCT06855745 | Alphyn Biologics | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis NCT07071610 | Lynk Pharmaceuticals Co., Ltd | Phase 2 |
| Recruiting | Herbal Ointment in Treating Atopic Dermatitis Topically NCT06850311 | En Chu Kong Hospital | Phase 2 / Phase 3 |
| Recruiting | A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) NCT06808477 | Bambusa Therapeutics | Phase 1 |
| Completed | Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis NCT07017348 | Pierre Fabre Dermo Cosmetique | N/A |
| Completed | Evaluation of the Efficacy of a Dermocosmetic Product RT00401-GO0046 on Atopic Dermititis Severity in Subjects NCT06763939 | Pierre Fabre Dermo Cosmetique | — |
| Recruiting | French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) NCT06837454 | Sanofi | — |
| Recruiting | Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis NCT06801821 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Enrolling By Invitation | Frequency of Food Allergy Confirm by Oral Food Challenge Among Foods Avoidance in Atopic Dermatitis Children NCT06947252 | Mahidol University | N/A |
| Not Yet Recruiting | A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis NCT06767540 | Akeso | Phase 3 |
| Recruiting | A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations i NCT06815380 | Almirall, S.A. | — |
| Enrolling By Invitation | Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis NCT06464133 | University of Pennsylvania | — |
| Not Yet Recruiting | Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients NCT06465732 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| Not Yet Recruiting | Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials NCT06174493 | Power Life Sciences Inc. | — |
| Not Yet Recruiting | A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) NCT06756126 | Akeso | Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Tha NCT06701331 | AbbVie | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatm NCT06718101 | AbbVie | Phase 2 |
| Active Not Recruiting | A Study of Barzolvolimab in Patients With Atopic Dermatitis NCT06727552 | Celldex Therapeutics | Phase 2 |
| Recruiting | Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products I NCT06930365 | NAOS Les Laboratoires | N/A |
| Not Yet Recruiting | A Clinical Study to Assess the Safety and Effectiveness of Test Products in Mild to Moderate Atopic Dermatitis NCT06687512 | NovoBliss Research Pvt Ltd | N/A |
| Recruiting | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis NCT06775860 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 |
| Active Not Recruiting | Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain NCT06415175 | Sanofi | — |
| Recruiting | FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients NCT06564389 | Pfizer | Phase 1 |
| Completed | Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in NCT07016087 | Federico II University | N/A |
| Recruiting | Cardamom and Topical Roseomonas in Atopic Dermatitis NCT06096857 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Effects of an Emollient Containing Postbiotic Saccharomyces and Lactobacillus on Pediatric Atopic Dermatitis NCT06474728 | Children's Hospital of Fudan University | N/A |
| Not Yet Recruiting | Allergy, Asthma, and Atopic Eczema in Finland NCT06330974 | Tampere University | — |
| Not Yet Recruiting | Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic NCT06599411 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Topical Treatment for Atopic Dermatitis NCT06244212 | Wake Forest University Health Sciences | N/A |
| Terminated | Topical ENS-002 for Atopic Dermatitis in Adults NCT06469385 | Concerto Biosciences | Phase 1 |
| Enrolling By Invitation | A Phase I Clinical Trial to Evaluate CU-10101 Unguent NCT06744569 | Cutia Therapeutics（Wuxi）Co.,Ltd | Phase 1 |
| Recruiting | Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Der NCT06756438 | NAOS Les Laboratoires | N/A |
| Completed | Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis NCT06553209 | Keymed Biosciences Co.Ltd | Phase 1 |
| Recruiting | AI App for Management of Atopic Dermatitis NCT06362629 | West China Hospital | N/A |
| Not Yet Recruiting | To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic De NCT06552520 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 |
| Completed | A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent® NCT06614907 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Du NCT06461897 | AbbVie | Phase 3 |
| Completed | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis NCT06585202 | Aclaris Therapeutics, Inc. | Phase 2 |
| Recruiting | A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or NCT06524635 | AbbVie | Phase 2 |
| Recruiting | Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Derm NCT05042258 | Northwestern University | Phase 4 |
| Recruiting | Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic De NCT06397911 | Oneness Biotech Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants NCT06438263 | Amgen | Phase 1 |
| Active Not Recruiting | Study of CM310 in Adolescent Subjects With Atopic Dermatis NCT06495229 | Keymed Biosciences Co.Ltd | Phase 3 |
| Recruiting | IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients NCT06765005 | Shanghai Mabgeek Biotech.Co.Ltd | Phase 1 / Phase 2 |
| Recruiting | Characterisation of Skin Microstructure Under Normal and Atrophied States NCT06954272 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Completed | Adding Auricular Acupuncture to Xiao-Feng-San Decoction for Treating Atopic Dermatitis NCT06492902 | University of Medicine and Pharmacy at Ho Chi Minh City | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis NCT06700499 | Akeso | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Sever NCT06477835 | Simcere Pharmaceutical Co., Ltd | Phase 3 |
| Not Yet Recruiting | Evaluation of Efficacy and Safety of Enhanced External Counter-pulsation on Patients With Atopic Dermatitis an NCT06448702 | The University of Hong Kong | N/A |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-A NCT06342713 | BeiGene | Phase 1 |
| Completed | Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis NCT06309355 | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Phase 2 |
| Not Yet Recruiting | Clinical Study of Trilinolein Cream for Prevention of Relapse in Remission of Moderate-to-severe Atopic Dermat NCT06463353 | Shanghai Yueyang Integrated Medicine Hospital | N/A |
| Recruiting | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Respons NCT06389136 | AbbVie | Phase 3 |
| Recruiting | A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers NCT06082323 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 1 |
| Recruiting | A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Chi NCT06311682 | LEO Pharma | Phase 3 |
| Recruiting | An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants W NCT06421740 | AbbVie | — |
| Completed | Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis NCT06444165 | Eli Lilly and Company | Phase 3 |
| Withdrawn | A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Mod NCT06390722 | AbbVie | Phase 3 |
| Recruiting | Virtual Reality for Pain Management During Dupilumab Injection NCT06182436 | St. Justine's Hospital | N/A |
| Recruiting | Nationwide Research on the Rewilding of Kindergarten Yards NCT06390878 | Natural Resources Institute Finland | N/A |
| Completed | MYCobiome Analysis in Atopic Dermatitis With Head and Neck Involvement NCT06455891 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Dietary Intervention on Atopy NCT06547372 | National University of Singapore | N/A |
| Completed | A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis NCT06436183 | Apollo Therapeutics Ltd | Phase 2 |
| Withdrawn | A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patien NCT06055374 | Brexogen Inc. | Phase 1 |
| Recruiting | A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Derm NCT06383468 | Akeso | Phase 3 |
| Active Not Recruiting | A Study Evaluating APG777 in Atopic Dermatitis NCT06395948 | Apogee Therapeutics, Inc. | Phase 2 |
| Completed | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermati NCT06238817 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderat NCT06280716 | Eli Lilly and Company | Phase 3 |
| Active Not Recruiting | The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatit NCT07098000 | Hospital Italiano de Buenos Aires | — |
| Completed | Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD NCT06345404 | Corvus Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study of TDM-180935 in Atopic Dermatitis Patients NCT06363461 | Technoderma Medicines Inc. | Phase 2 |
| Completed | TRacking Atopic Dermatitis Infants and Their Microbiome (TRAM) NCT06578351 | Danone Asia Pacific Holdings Pte, Ltd. | — |
| Completed | A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopi NCT06224192 | Amgen | Phase 3 |
| Recruiting | Dupilumab De-escalation in Pediatric Atopic Dermatitis NCT06116526 | Johns Hopkins University | Phase 4 |
| Unknown | A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis NCT06116565 | Keymed Biosciences Co.Ltd | Phase 2 |
| Completed | Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis NCT06277765 | Keymed Biosciences Co.Ltd | Phase 3 |
| Recruiting | A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis NCT06587685 | Prime Gene Therapeutics Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Study of TAVO101 in Atopic Dermatitis Patients NCT06176040 | Tavotek Biotherapeutics | Phase 2 |
| Recruiting | Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis NCT06448689 | ActiGraph L.L.C | — |
| Completed | Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life NCT06427122 | Tamar Nijsten | N/A |
| Active Not Recruiting | Phase 2 Trial of HY209gel in Atopic Dermatitis Patients NCT06024499 | Shaperon | Phase 2 |
| Unknown | Involvement of Pollutants in Atopic Dermatitis and Psoriasis NCT06213688 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin NCT06324695 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Completed | A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants NCT06268860 | Amgen | Phase 1 |
| Recruiting | Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project NCT06300697 | University of Michigan | N/A |
| Completed | A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. NCT06277245 | Lynk Pharmaceuticals Co., Ltd | Phase 3 |
| Completed | Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis NCT07537751 | Noura Abdelmoneim Mohammed Elseessy | N/A |
| Completed | A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants NCT06214481 | Amgen | Phase 1 |
| Recruiting | Registry for Systemic Eczema Treatments NCT06136767 | Johns Hopkins University | — |
| Unknown | Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis NCT06026891 | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 |
| Recruiting | The Potential Role of Compounds Derived From Ultra-processed Foods in the Pathogenesis of Atopic Dermatitis in NCT06996327 | Federico II University | — |
| Completed | Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms NCT06268847 | Abyss Ingredients | N/A |
| Unknown | Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis NCT06216392 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 |
| Completed | Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis NCT06162507 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Completed | Evaluation of the Efficacy of TOPIALYSE Baume Protect+ on Atopic Dermatis NCT06108570 | SVR Group | N/A |
| Unknown | A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermat NCT06319781 | Blueskin AS | — |
| Completed | An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psorias NCT06275659 | Click Therapeutics, Inc. | N/A |
| Recruiting | CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry NCT06238765 | CorEvitas | — |
| Unknown | A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. NCT06175143 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Nutritional Study to Determine the Effect of Fish Oil on Atopic Dermatitis NCT06194045 | Møreforsking AS | N/A |
| Active Not Recruiting | A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Re NCT06169527 | Sanofi | — |
| Completed | A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Ato NCT07103369 | SinoMab BioScience Ltd | Phase 1 |
| Active Not Recruiting | Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic De NCT05990725 | Almirall, S.A. | Phase 3 |
| Completed | A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis NCT06058000 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis NCT06058156 | Sanofi | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis NCT06092762 | Akeso | Phase 2 |
| Active Not Recruiting | Bodewell Products for the Treatment of Atopic Dermatitis NCT05566262 | University of Alabama at Birmingham | Phase 4 |
| Terminated | A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis NCT06119529 | Eli Lilly and Company | Phase 1 |
| Unknown | Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis NCT06101823 | Opsidio, LLC | Phase 2 |
| Completed | Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmac NCT06144424 | Escient Pharmaceuticals, Inc | Phase 2 |
| Recruiting | Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers NCT05994976 | Innovaderm Research Inc. | — |
| Recruiting | Drug Survival of Target Therapies in Atopic Dermatitis NCT06882148 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Al NCT05544448 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Clinical Observation of Topical Lidocaine Cream Combined With Moisturizing Cream in the Treatment of Atopic De NCT07067541 | First Affiliated Hospital of Kunming Medical University | N/A |
| Active Not Recruiting | A Herbal Compound for Eczema NCT06758752 | Fasa University of Medical Sciences | Phase 2 |
| Unknown | Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Mode NCT06366932 | Instituto de Investigación Hospital Universitario La Paz | Phase 4 |
| Completed | A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe NCT05923099 | LEO Pharma | Phase 2 |
| Recruiting | Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed NCT06259669 | Incyte Corporation | — |
| Active Not Recruiting | Tralokinumab for Dupilumab Failures NCT06773455 | Psoriasis Treatment Center of Central New Jersey | Phase 4 |
| Completed | A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic NCT05958407 | LEO Pharma | Phase 3 |
| Recruiting | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe NCT05995964 | Pfizer | Phase 2 |
| Completed | The Effect of Nature-based Exposure on the Immune System and Skin Health of Atopic Dermatitis Patients. NCT06129136 | Uute Scientific Oy | N/A |
| Completed | Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis NCT05969730 | Mazandaran University of Medical Sciences | N/A |
| Recruiting | DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema NCT06004986 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 |
| Completed | A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) NCT06673654 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Terminated | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD NCT05984784 | Inmagene LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | The Role of Human Milk Oligosaccharides and Microbiomes on Infantile Colic and Atopic Dermatitis in Term Infan NCT05992493 | National Cheng-Kung University Hospital | — |
| Completed | POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis NCT05932654 | Biosion, Inc. | Phase 2 |
| Completed | Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to M NCT06009094 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 |
| Recruiting | A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring NCT05721937 | Pfizer | — |
| Unknown | The Therapeutic Effects of Topical Cannabidiol (CBD) Products for Atopic Dermatitis NCT06022874 | Phoilex Ltd. | — |
| Unknown | A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD NCT05905133 | Connect Biopharm LLC | Phase 2 |
| Completed | Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese NCT05945810 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. NCT06553287 | Lynk Pharmaceuticals Co., Ltd | Phase 1 |
| Completed | Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects NCT05932888 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis NCT05911841 | Eli Lilly and Company | Phase 2 |
| Unknown | A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis NCT05970432 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | NiPPeR Randomised Trial - Child Follow Up Study NCT05934422 | University of Southampton | N/A |
| Unknown | A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological NCT05084417 | OM1, Inc. | — |
| Completed | A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCK NCT05899816 | Amgen | Phase 3 |
| Completed | Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 NCT05891119 | Amgen | EARLY_Phase 1 |
| Active Not Recruiting | Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients (ADAMUNE) NCT05868824 | Centre Hospitalier Universitaire de Nice | N/A |
| Active Not Recruiting | A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Partici NCT05882877 | Amgen | Phase 3 |
| Completed | A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants Wi NCT05507580 | AbbVie | Phase 4 |
| Recruiting | Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis NCT06390696 | Natural Resources Institute Finland | N/A |
| Active Not Recruiting | Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atop NCT05916365 | Almirall, S.A. | Phase 3 |
| Terminated | Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD) NCT05859724 | Yellow Jersey Therapeutics AG | Phase 1 |
| Completed | Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis NCT05833880 | Central Hospital, Nancy, France | — |
| Completed | Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis NCT05844618 | Innovaderm Research Inc. | Phase 4 |
| Unknown | A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Heal NCT05952986 | Oneness Biotech Co., Ltd. | Phase 1 |
| Recruiting | Determinants of Chronic Inflammatory Skin Disease Trajectories NCT05928169 | University Hospital Schleswig-Holstein | — |
| Unknown | Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal NCT05688735 | Integrative Skin Science and Research | N/A |
| Completed | A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatiti NCT05704738 | Amgen | Phase 3 |
| Recruiting | A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injectio NCT06055361 | Brexogen Inc. | Phase 1 |
| Unknown | Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy NCT05662800 | Medical University of Warsaw | — |
| Unknown | Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis NCT05969717 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Unknown | Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children NCT05613062 | Chinese University of Hong Kong | Phase 1 / Phase 2 |
| Completed | A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers NCT05718921 | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Phase 1 |
| Unknown | The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical NCT05719649 | SunWay Biotech Co., LTD. | N/A |
| Recruiting | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolit NCT06627335 | Incyte Corporation | — |
| Terminated | The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Exp NCT05696392 | Incyte Corporation | Phase 4 |
| Recruiting | Mind and Skin - the Neurocutaneous Axis in Atopic Eczema NCT05790330 | King's College London | — |
| Completed | Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis NCT05715320 | Keymed Biosciences Co.Ltd | Phase 2 |
| Enrolling By Invitation | A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <1 NCT05735483 | Eli Lilly and Company | Phase 3 |
| Recruiting | A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis. NCT05689151 | Pfizer | — |
| Active Not Recruiting | Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis NCT05642208 | Nantes University Hospital | Phase 4 |
| Recruiting | Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Derm NCT06039241 | Sanofi | — |
| Unknown | A First-in-Human Study of QY211 Gel in Adult Subjects NCT05843422 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Phase 1 |
| Unknown | Ophthalmological Adverse Events of Tralokinumab in AD NCT05682976 | Nantes University Hospital | — |
| Completed | Clinic-Based Atopic Dermatitis Therapeutic Patient Education NCT04352270 | Boston University | N/A |
| Completed | Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China NCT05680298 | Sanofi | Phase 4 |
| Active Not Recruiting | The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema) NCT05704205 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Active Not Recruiting | An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and NCT05669794 | AbbVie | — |
| Completed | A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitor NCT05724199 | Amgen | Phase 3 |
| Completed | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) NCT05717920 | Aldeyra Therapeutics, Inc. | Phase 2 |
| Completed | Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis NCT06509243 | Medical University of Silesia | N/A |
| Unknown | The Study of CM326 in Adult Subjects With Atopic Dermatitis NCT05671445 | Keymed Biosciences Co.Ltd | Phase 2 |
| Recruiting | Multi-modal Quantitative Imaging of the Skin NCT06989216 | HJN Sverige AB/Neko Health | — |
| Recruiting | Molecular Signatures of Cutaneous Dupilumab Response NCT05858619 | University of California, San Francisco | Phase 4 |
| Active Not Recruiting | Patient with Atopic Dermatitis' Needs for Self-management Support - Flexible Patient Centred Consultations NCT06032403 | University Hospital, Gentofte, Copenhagen | N/A |
| Completed | A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moder NCT05633355 | Amgen | Phase 3 |
| Recruiting | Ethnic Differences in Mechanisms of Action of Dupilumab NCT05268107 | University of Michigan | Phase 4 |
| Completed | Periodontal Status in Patients With Chronic Skin Diseases NCT06073613 | University of Medicine and Pharmacy at Ho Chi Minh City | — |
| Terminated | A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) W NCT05732454 | Pfizer | Phase 2 / Phase 3 |
| Completed | A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants Wit NCT05372419 | Eli Lilly and Company | Phase 3 |
| Unknown | A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe NCT05676242 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Terminated | A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis NCT05491447 | BioMimetix JV, LLC | Phase 2 |
| Unknown | Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema NCT05790083 | Bionorica SE | N/A |
| Withdrawn | Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone NCT04325802 | University of Minnesota | Phase 2 |
| Completed | A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermat NCT05527964 | Sanofi | — |
| Completed | A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to P NCT05656911 | Bayer | Phase 2 |
| Unknown | Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With D NCT05694884 | ASLAN Pharmaceuticals | Phase 2 |
| Completed | A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermat NCT05369403 | Eli Lilly and Company | Phase 3 |
| Unknown | Effects of a Mixed Chinese Herbal Formula on Atopic Dermatitis NCT05455060 | Chang Gung Memorial Hospital | Phase 3 |
| Completed | A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Hori NCT05651711 | Amgen | Phase 3 |
| Recruiting | Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada NCT05938478 | University of California, San Diego | — |
| Completed | A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type At NCT05451316 | AbbVie | — |
| Withdrawn | CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis NCT05614817 | Connect Biopharm LLC | Phase 3 |
| Unknown | The Transcriptomic Study of Thai Patients With Atopic Dermatitis by Tape Strips NCT05598762 | Queen Sirikit National Institute of Child Health | N/A |
| Completed | Therapist-guided vs Self-guided CBT for AD: Non-inferiority Trial NCT05517850 | Karolinska Institutet | N/A |
| Completed | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous NCT05601882 | AbbVie | Phase 3 |
| Completed | Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With NCT05602207 | Innovaderm Research Inc. | Phase 4 |
| Completed | Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China NCT05624112 | Sanofi | Phase 4 |
| Withdrawn | Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis NCT05016284 | Applied Biology, Inc. | Phase 3 |
| Completed | Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis NCT05436535 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Recruiting | Meditation in Inflammatory Dermatosis NCT05500794 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Methodological Study of the Effect of a Lotion Containing Nature Based Microbial Extract on Atopic Skin NCT06499766 | Uute Scientific Oy | N/A |
| Completed | Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermat NCT05487963 | CAGE Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive NCT05575882 | NAOS Argentina S.A. | N/A |
| Completed | Atopic Dermatitis With Accelerometry and Polysomnography (ADAP) NCT05583019 | SymmetryScience Group, Inc. | — |
| Completed | Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric Patients NCT05259774 | Relife S.r.l. | N/A |
| Completed | Staphylococcus Aureus in Atopic Dermatitis Immunopathology NCT04715087 | Hospices Civils de Lyon | N/A |
| Unknown | Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis NCT05578482 | Jacob Pontoppidan Thyssen | Phase 4 |
| Active Not Recruiting | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopi NCT05559359 | Eli Lilly and Company | Phase 3 |
| Unknown | Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response NCT05692843 | Instituto de Investigación Hospital Universitario La Paz | Phase 4 |
| Terminated | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis NCT06005792 | Xencor, Inc. | Phase 1 |
| Completed | A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis NCT05579925 | Keymed Biosciences Co.Ltd | Phase 2 |